227 related articles for article (PubMed ID: 36227357)
1. Combination of pre-treatment dynamic [
Li Z; Holzgreve A; Unterrainer LM; Ruf VC; Quach S; Bartos LM; Suchorska B; Niyazi M; Wenter V; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL; Kaiser L
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):535-545. PubMed ID: 36227357
[TBL] [Abstract][Full Text] [Related]
2. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [
Li Z; Kaiser L; Holzgreve A; Ruf VC; Suchorska B; Wenter V; Quach S; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4415-4425. PubMed ID: 34490493
[TBL] [Abstract][Full Text] [Related]
3. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
5. Static
Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
[TBL] [Abstract][Full Text] [Related]
6.
Wiltgen T; Fleischmann DF; Kaiser L; Holzgreve A; Corradini S; Landry G; Ingrisch M; Popp I; Grosu AL; Unterrainer M; Bartenstein P; Parodi K; Belka C; Albert N; Niyazi M; Riboldi M
Radiat Oncol; 2022 Dec; 17(1):198. PubMed ID: 36461120
[TBL] [Abstract][Full Text] [Related]
7. Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [
Kaiser L; Quach S; Zounek AJ; Wiestler B; Zatcepin A; Holzgreve A; Bollenbacher A; Bartos LM; Ruf VC; Böning G; Thon N; Herms J; Riemenschneider MJ; Stöcklein S; Brendel M; Rupprecht R; Tonn JC; Bartenstein P; von Baumgarten L; Ziegler S; Albert NL
Eur J Nucl Med Mol Imaging; 2024 Feb; ():. PubMed ID: 38396261
[TBL] [Abstract][Full Text] [Related]
8. Integrated CT Radiomics Features Could Enhance the Efficacy of
Zhou W; Huang Q; Wen J; Li M; Zhu Y; Liu Y; Dai Y; Guan Y; Zhou Z; Hua T
Front Oncol; 2021; 11():772703. PubMed ID: 34869011
[TBL] [Abstract][Full Text] [Related]
9. Static and dynamic
Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement.
Rosen J; Stoffels G; Lohmann P; Bauer EK; Werner JM; Wollring M; Rapp M; Felsberg J; Kocher M; Fink GR; Langen KJ; Galldiks N
Sci Rep; 2021 Oct; 11(1):20828. PubMed ID: 34675225
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
[TBL] [Abstract][Full Text] [Related]
12. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
[TBL] [Abstract][Full Text] [Related]
14. Sequential implementation of DSC-MR perfusion and dynamic [
Steidl E; Langen KJ; Hmeidan SA; Polomac N; Filss CP; Galldiks N; Lohmann P; Keil F; Filipski K; Mottaghy FM; Shah NJ; Steinbach JP; Hattingen E; Maurer GD
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1956-1965. PubMed ID: 33241456
[TBL] [Abstract][Full Text] [Related]
15. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?
Piroth MD; Liebenstund S; Galldiks N; Stoffels G; Shah NJ; Eble MJ; Coenen HH; Langen KJ
Mol Imaging; 2013 Sep; 12(6):388-95. PubMed ID: 23981784
[TBL] [Abstract][Full Text] [Related]
17. Predicting IDH genotype in gliomas using FET PET radiomics.
Lohmann P; Lerche C; Bauer EK; Steger J; Stoffels G; Blau T; Dunkl V; Kocher M; Viswanathan S; Filss CP; Stegmayr C; Ruge MI; Neumaier B; Shah NJ; Fink GR; Langen KJ; Galldiks N
Sci Rep; 2018 Sep; 8(1):13328. PubMed ID: 30190592
[TBL] [Abstract][Full Text] [Related]
18. TSPO PET signal using [
Quach S; Holzgreve A; Kaiser L; Unterrainer M; Dekorsy FJ; Nelwan DV; Bartos LM; Kirchleitner SV; Weller J; Weidner L; Niyazi M; Ruf VC; Herms J; Stöcklein S; Wetzel C; Riemenschneider MJ; V Baumgarten L; Thon N; Brendel M; Rupprecht R; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):859-869. PubMed ID: 36329288
[TBL] [Abstract][Full Text] [Related]
19. FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
Carles M; Popp I; Starke MM; Mix M; Urbach H; Schimek-Jasch T; Eckert F; Niyazi M; Baltas D; Grosu AL
Radiat Oncol; 2021 Mar; 16(1):46. PubMed ID: 33658069
[TBL] [Abstract][Full Text] [Related]
20. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.
Pyka T; Gempt J; Hiob D; Ringel F; Schlegel J; Bette S; Wester HJ; Meyer B; Förster S
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):133-141. PubMed ID: 26219871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
